Passage Bio, Inc. Stock Price, News & Analysis

Passage Bio (NASDAQ: PASG) announced its participation in two virtual investor conferences in June 2021. The Jefferies Healthcare Conference will take place on June 2 at 4:30 p.m. ET, featuring a presentation format. On June 10, Passage Bio will engage in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference at 11:20 a.m. ET. Both events will be available via live webcast on the company's website, with replays accessible for 30 days post-event. As a clinical-stage genetic medicines firm, Passage Bio focuses on innovative therapies for rare CNS disorders.

Passage Bio (Nasdaq: PASG) announced a significant presentation by the University of Pennsylvania’s Gene Therapy Program at the ASGCT annual meeting, showcasing a new mouse model to evaluate gene therapy efficacy for metachromatic leukodystrophy (MLD). Preliminary results indicate that Passage Bio’s candidate PBML04 showed promising efficacy, reducing neurological deficits in this model. This advancement addresses the challenge of limited mouse models for MLD, facilitating the preclinical evaluation of AAV-mediated gene therapy. The company aims to advance its IND-enabling studies for PBML04.

Passage Bio (Nasdaq: PASG) will host its second virtual Research & Development event on May 17, 2021, focusing on frontotemporal dementia (FTD) with granulin mutations. This presentation will include robust pre-clinical data and insights into the clinical program for PBFT02, a gene therapy for FTD. Key speakers include Eliseo O. Salinas and Christian Hinderer, among others. The event will feature a Q&A session with prominent experts. The live webcast will be accessible on the company's website for 30 days after the event.

Passage Bio (NASDAQ: PASG) reported a net loss of $38.9 million for Q1 2021, with cash and equivalents at $437.6 million after a $166 million public offering. The company initiated its Phase 1/2 Imagine-1 trial for PBGM01, focused on infantile GM1 gangliosidosis, and expects the first patient for the FTD-GRN trial by 2Q/3Q 2021. Regulatory approvals were obtained for three advanced pipeline programs, including PBFT02 and PBKR03. Despite COVID-19-related delays, Passage Bio aims to reveal initial safety and biomarker data for its trials in 4Q21 and 1H22.

Passage Bio (NASDAQ: PASG) announced a collaboration with InformedDNA to offer no-cost genetic counseling and testing for adults diagnosed with Frontotemporal Dementia (FTD). The initiative aims to identify patients with inherited genetic mutations, facilitating early treatment and clinical trial recruitment. FTD affects 50,000–60,000 Americans and is a leading cause of dementia under age 65. Additionally, Passage Bio is developing PBFT02, a gene therapy for FTD with granulin mutations, which is slated for a Phase 1/2 clinical study.

Passage Bio (NASDAQ: PASG) is set to announce its Q1 2021 financial results on May 5, 2021, during a conference call at 8:30 a.m. ET. The call will provide updates on recent business highlights in genetic medicines focused on rare CNS disorders. Interested parties can join the call by dialing 833-528-0605 (domestic) or 830-221-9111 (international). A live audio webcast will also be available on the company's investors page.

The company is partnered with the University of Pennsylvania for gene therapy innovations.

Passage Bio announced that the European Commission granted Orphan designation for its investigational gene therapy PBKR03, aimed at treating Krabbe disease, which currently has no approved therapies. The therapy, utilizing a proprietary AAV delivery method, is expected to begin a global Phase 1/2 trial, GALax-C, in the first half of 2021. This designation, along with previous FDA recognitions, emphasizes the urgency for effective treatments for this severe disease. Preclinical data indicate significant potential in improving myelination and clinical outcomes.

Passage Bio has progressed its PBGM01 gene therapy into clinical development, marking a significant milestone for the company. The first patient was dosed in the global Phase 1/2 Imagine-1 trial to treat infantile GM1 gangliosidosis, which affects approximately 0.5 to 1 in 100,000 live births. The trial aims to assess the safety, tolerability, and efficacy of PBGM01. Passage Bio anticipates releasing initial safety and biomarker data in mid-2021, with plans to open 10 clinical sites globally, enhancing its research capacity.

Passage Bio, a genetic medicines company focused on therapies for rare CNS disorders, announces participation in three virtual investor conferences. The events are scheduled for April 1, 13, and 26, 2021. The company aims to showcase its advancements in gene therapies and engage with investors. Webcasts of the events will be available on the company’s website, with replays for 30 days. Passage Bio collaborates with the University of Pennsylvania’s Gene Therapy Program to expedite its pipeline development. For more information, visit passagebio.com.